跳至主要内容
临床试验/2023-507991-32-00
2023-507991-32-00已完成4 期

An open label, balanced, randomized, single dose, two treatment, two period, two sequence, crossover, bioequivalence study comparing Lacosamide tablets USP 200 mg, manufactured by Sun Laboratories Industries Limited, India with Vimpat (Lacosamide) 200 mg film-coated tablets, Marketing Authorisation Holder UCB Pharma S.A., Belgium, in healthy adult, human subjects under fasting condition.

Sun Pharmaceutical Industries Limited1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2024年2月19日最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
32
试验地点
1

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

Arshad Khuroo

Scientific

Sun Pharmaceutical Industries Limited

研究点 (1)

Loading locations...

相似试验

招募中
4 期
An open-label, randomized, single-dose, three-way crossover trial to evaluate the pharmacokinetics of nicotine pouch (NP) dry 4 mg compared with Nicorette® lozenge 4 mg in healthy adults who use cigarettes
2025-523879-34-00Swedish Match North Europe AB72
已完成
4 期
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fed condition.Atopic dermatitisPsoriatic arthritisUlcerative colitisRheumatoid arthritis
2024-512771-12-00Sun Pharmaceutical Industries Limited32
已完成
4 期
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Brivaracetam Tablets Ph. Eur. 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Briviact (brivaracetam) 100 mg film-coated tablets, Marketing Authorisation Holder: UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgium; Manufactured by UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium, in healthy adult, human subjects under fasting condition.Epilepsy
2024-516500-42-00Sun Pharmaceutical Industries Limited36
已完成
4 期
Randomized, Open-label, Single-Dose, Two-treatment, Two-period, Cross-over, Pivotal Bioequivalence Study Comparing Amoxicilin/Clavulanic acid powder for oral suspension 600 mg/42.9 mg/5 mL to Augemntin ES 600 mg/42.9 mg/5 mL powder for oral suspension in Healthy Adult Male and Female Volunteers under Fed Conditions.
2023-503233-22-00Tarchominskie Zaklady Farmaceutyczne Polfa S.A.56
已完成
1 期
Comparative assessment of the absorption of a generic formulation of asenapine sublingual tablet against the innovator asenapine sublingual tablet conducted under fasting conditions in healthy male and female volunteersBioequivalence study on asenapine formulations.Schizophrenia in adultsOther - Research that is not of generic health relevance and not applicable to specific health categories listed aboveMental Health - Schizophrenia
ACTRN12613000650796Zenith Technology Corporation Limited36
An open label, balanced, randomized, single dose,... | 临床试验